Lawrence Fong, a genitourinary oncologist and expert in immunotherapy for solid tumors, was named scientific director of the Immunotherapy Integrated Research Center at Fred Hutchinson Cancer Center. He will begin the role July 1, 2024.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
